Information Provided By:
Fly News Breaks for March 24, 2015
MEIP
Mar 24, 2015 | 06:56 EDT
Cantor cut its price target on MEI Pharma due to the lack of tolerability which caused the failure of the Phase 2 trial of the company's Pracinostat and azacitidine drugs, according to the firm. However, the firm believes that the data justifies producing the drug at "more tolerant dosing" levels, and it keeps a Buy rating on the shares.
News For MEIP From the Last 2 Days
There are no results for your query MEIP